ENTA
NASDAQEnanta Pharmaceuticals Inc.
Website
News25/Ratings12
News · 26 weeks58-73%
2025-10-262026-04-19
Mix3090d
- Insider12(40%)
- SEC Filings8(27%)
- Other8(27%)
- Earnings1(3%)
- Analyst1(3%)
Latest news
25 items- PREnanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of UrticariaPhase 1 Study Will Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EDP-978 in Healthy Volunteers Topline Data Expected in Q4 2026 Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that the first participant has been dosed in a Phase 1 clinical trial of EDP-978, an oral, once-daily KIT inhibitor in development for urticaria and other mast cell-driven diseases. The Phase 1 single-ascending dose (SAD) and multiple-ascending dose (MAD) clinical trial will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodyn
- PREnanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that data on zelicapavir, an oral, once-daily, N-protein inhibitor, in development for the treatment of (RSV) have been accepted for two oral presentations at the European Society of Clinical Microbiology & Infectious Diseases Global 2026 (ESCMID) being held April 17-21, 2025 in Munich, Germany. The first oral presentation will include results from RSVHR, the Phase 2b study of zelicapavir in high-risk adults, which were announced in September 2025, showing about a week improvement in complete symptom r
- PREnanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that preclinical data from the Company's STAT6 inhibitor program will be presented in four posters at IMMUNOLOGY2026™, the annual meeting of the American Association of Immunologists (AAI), being held April 15-19, 2026 in Boston, MA. Details of the presentations are as follows: Poster Number: 573 Abstract Number: 2257506 Title: Oral STAT6 Inhibitor EPS-3903 Demonstrates Good Preclinical In Vivo Tolerability without Reactive Metabolites or Metabolic/Safety Liabilities Date: Thursday, April 16, 2026 Ti
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Enanta Pharmaceuticals Inc.SCHEDULE 13G/A - ENANTA PHARMACEUTICALS INC (0001177648) (Subject)
- ANALYSTRodman & Renshaw initiated coverage on Enanta Pharmaceuticals with a new price targetRodman & Renshaw initiated coverage of Enanta Pharmaceuticals with a rating of Buy and set a new price target of $20.00
- SECEnanta Pharmaceuticals Inc. filed SEC Form 8-K: Other Events8-K - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)
- INSIDERSEC Form 4 filed by Director Vance Terry4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
- INSIDERSEC Form 4 filed by Director Russell Lesley4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
- INSIDERSEC Form 4 filed by Director Peterson Kristine4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
- INSIDERSEC Form 4 filed by Director Hata Yujiro S4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
- INSIDERSEC Form 4 filed by Director Foletta Mark G4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
- INSIDERSEC Form 4 filed by Director Carter Bruce L A4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
- SECEnanta Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)
- PREnanta Pharmaceuticals to Present at The Citizens Life Sciences ConferenceEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that members of management will participate in a fireside chat at The Citizens Life Sciences Conference on Tuesday, March 10, 2026 at 10:45 a.m. ET in Miami Beach, FL. A live webcast of the event will be accessible by visiting the "Events and Presentations" section on the "Investors" page of Enanta's website at www.enanta.com. A replay of the webcast will be available following the presentation and will be archived for at least 30 days. About Enanta Pharmaceuticals, Inc. Enanta is using its robust, c
- SECSEC Form EFFECT filed by Enanta Pharmaceuticals Inc.EFFECT - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)
- INSIDERChief Legal Officer Kowalsky Matthew Paul was granted 5,493 shares and covered exercise/tax liability with 1,902 shares (SEC Form 4)4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
- INSIDERChief Business Officer Luu Brendan covered exercise/tax liability with 3,257 shares and was granted 6,562 shares, increasing direct ownership by 9% to 41,634 units (SEC Form 4)4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
- INSIDERChief Product Strategy Officer Kieffer Tara Lynn was granted 6,562 shares and covered exercise/tax liability with 3,257 shares, increasing direct ownership by 11% to 33,925 units (SEC Form 4)4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
- INSIDERChief Medical Officer Rottinghaus Scott T. was granted 6,875 shares and covered exercise/tax liability with 3,413 shares, increasing direct ownership by 16% to 25,254 units (SEC Form 4)4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
- INSIDERChief Scientific Officer Or Yat Sun was granted 6,875 shares and covered exercise/tax liability with 3,413 shares, increasing direct ownership by 0.93% to 374,854 units (SEC Form 4)4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
- INSIDERPresident and CEO Luly Jay R. was granted 20,000 shares and covered exercise/tax liability with 6,155 shares, increasing direct ownership by 2% to 871,871 units (SEC Form 4)4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Enanta Pharmaceuticals Inc.SCHEDULE 13G/A - ENANTA PHARMACEUTICALS INC (0001177648) (Subject)
- SECSEC Form S-3 filed by Enanta Pharmaceuticals Inc.S-3 - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)
- SECSEC Form 10-Q filed by Enanta Pharmaceuticals Inc.10-Q - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)
- PREnanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual MeetingEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that preclinical data for EDP-978, the Company's KIT inhibitor in development for the treatment of mast cell-mediated, Type 2 immune diseases, will be presented in two poster presentations at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting being held February 27 – March 2, 2026 in Philadelphia, PA. Details of the presentations are as follows: Abstract Title: Discovery of a Potent and Selective KIT inhibitor for Treatment of Mast Cell-Mediated Diseases Date: Friday, Fe